Format

Send to

Choose Destination
Radiother Oncol. 2016 Mar;118(3):478-84. doi: 10.1016/j.radonc.2015.12.026. Epub 2016 Jan 18.

A comparison between accelerated hypofractionation and stereotactic ablative radiotherapy (SABR) for early-stage non-small cell lung cancer (NSCLC): Results of a propensity score-matched analysis.

Author information

1
Department of Radiation Oncology, Sunnybrook Odette Cancer Centre, University of Toronto, Canada.
2
Département de Radio-Oncologie, Centre Hospitalier Universitaire de Québec, Canada.
3
Department of Radiation Oncology, London Regional Cancer Program, University of Western Ontario, Canada.
4
Centre for Cancer Research and Cell Biology, Queen's University Belfast, United Kingdom.
5
Department of Radiation Oncology, Sunnybrook Odette Cancer Centre, University of Toronto, Canada. Electronic address: patrick.cheung@sunnybrook.ca.

Abstract

BACKGROUND AND PURPOSE:

Stereotactic ablative radiotherapy (SABR) has become standard for inoperable early-stage non-small cell lung cancer (NSCLC). However, there is no randomized evidence demonstrating benefit over more fractionated radiotherapy. We compared accelerated hypofractionation (AH) and SABR using a propensity score-matched analysis.

MATERIALS AND METHODS:

From 1997-2007, 119 patients (T1-3N0M0 NSCLC) were treated with AH (48-60 Gy, 12-15 fractions). Prior to SABR, this represented our institutional standard. From 2008-2012, 192 patients (T1-3N0M0 NSCLC) were treated with SABR (48-52 Gy, 4-5 fractions). A total of 114 patients (57 per cohort) were matched (1:1 ratio, caliper: 0.10) using propensity scores.

RESULTS:

Median follow-up (range) for the AH cohort was 36.3 (2.5-109.1) months, while that for the SABR group was 32.5 (0.3-62.6)months. Three-year overall survival (OS) and local control (LC) rates were 49.5% vs. 72.4% [p=0.024; hazard ratio (HR): 2.33 (1.28, 4.23), p=0.006] and 71.9% vs. 89.3% [p=0.077; HR: 5.56 (1.53, 20.2), p=0.009], respectively. On multivariable analysis, tumour diameter and PET staging were predictive for OS, while the only predictive factor for LC was treatment cohort.

CONCLUSIONS:

OS and LC were improved with SABR, although OS is more closely related to non-treatment factors. This represents one of the few studies comparing AH to SABR for early-stage lung cancer.

KEYWORDS:

Accelerated hypofractionation; Lung cancer; Stereotactic radiotherapy

PMID:
26795773
DOI:
10.1016/j.radonc.2015.12.026
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center